Thursday, October 21, 2021

Natco files for patent waiver for arthritis drug to fight Covid-19 in Hyderabad – ET HealthWorld


In the first instance of a pharma company taking the compulsory licencing (CL) route to launch a Covid-19 drug in India, Hyderabad-based Natco Pharma has filed for a CL to manufacture rheumatoid arthritis drug Baricitinib, under Section 92 of the Patents Act, 1970. The patent is owned by Incyte Holdings, with a license to Eli Lilly, which markets the drug under the Olumiant brand name.

In its application, Natco has cited the unmet medical needs due to the lack of supply and affordability in light of the grave and life-threatening national public health emergency, due to the Covid-19 second wave, as the main grounds for seeking the CL.

“The CL, if granted, will help in improving the accessibility and affordability of the drug, bringing its price down substantially”.

Under the World Trade Organisation TRIPS Agreement, compulsory licences are legally-recognised means to overcome barriers in accessing affordable medicines. Under the rules, governments allow a company to manufacture a patented drug without the consent of the innovator firm.

Analysts said Natco’s move puts pressure on the US drug maker. It has only two choices – either give a voluntary licence or sue Natco for the patent, which could result in a public backlash given the soaring Covid-19 case load and death toll in India.

Natco has applied for a CL at a time when India and South Africa have approached the WTO for a temporary suspension of intellectual property rights of pharma companies so that Covid-19 vaccines and other medicines can be accessible to poor countries.

Natco has urged the controller of patents to grant it a CL to manufacture and market Baricitinib, both as bulk API (active pharmaceutical ingredient) and finished dosage only for Covid-19 treatment in India till the pandemic prevails. It is also willing to pay a 7% royalty on net profits from Baricitinib sales to the patent-holder.

Making its case, Natco’s application said not only is Olumiant not manufactured in India, less than 9,000 tablets were imported in 2019 and 2020, at an average cost of Rs 3,230 per tablet.

Citing the pricing as a significant barrier, it said a 14-day regimen (one tablet a day) works out to approximately Rs 45,220 per patient, which most Indians can ill-afford.

Natco said it would structure its pricing at Rs 30 each for a 4mg tablet, which translates to Rs 420 for a 14-day course, Rs 20 for a 2mg tablet (Rs 280 for the regimen) and Rs 15 for each 1mg tablet, costing only Rs 210 for the entire 14-day therapy.

It also pointed out that the drug’s limited imports, which dropped from 8,870 tablets in 2019 to 8,385 tablets in 2020, would not be enough to cater the nearly 34 lakh Covid-19 patients in India. “The tablets of Olumiant imported through 2020 by Lilly would serve at best to meet the needs of only approximately 600 patients,” Natco said in its application, a copy of which was reviewed by TOI.

“It’s time India set up an independent committee of experts to consider and advice on compulsory licensing and use of other safeguards for Covid-19 medical products including medicines and vaccines’’, lawyer and IP expert, Leena Menghaney told TOI.

This is not Natco’s first battle for CL with a global pharma biggie. In 2012-13 it took on Bayer for cancer drug Nexavar and won India’s first ever successful compulsory license.





Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...